ATE547106T1 - Cladribin dosierschema zur behandlung von multipler sklerose - Google Patents

Cladribin dosierschema zur behandlung von multipler sklerose

Info

Publication number
ATE547106T1
ATE547106T1 AT05823474T AT05823474T ATE547106T1 AT E547106 T1 ATE547106 T1 AT E547106T1 AT 05823474 T AT05823474 T AT 05823474T AT 05823474 T AT05823474 T AT 05823474T AT E547106 T1 ATE547106 T1 AT E547106T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
cladribine
treatment
dosage scheme
preparation
Prior art date
Application number
AT05823474T
Other languages
German (de)
English (en)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34930135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE547106(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Priority claimed from PCT/EP2005/056954 external-priority patent/WO2006067141A1/en
Application granted granted Critical
Publication of ATE547106T1 publication Critical patent/ATE547106T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
AT05823474T 2004-12-22 2005-12-20 Cladribin dosierschema zur behandlung von multipler sklerose ATE547106T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE547106T1 true ATE547106T1 (de) 2012-03-15

Family

ID=34930135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823474T ATE547106T1 (de) 2004-12-22 2005-12-20 Cladribin dosierschema zur behandlung von multipler sklerose

Country Status (11)

Country Link
AT (1) ATE547106T1 (sr)
CY (1) CY1125491T1 (sr)
DK (1) DK1827461T3 (sr)
ES (4) ES2428741T3 (sr)
HU (1) HUE035859T2 (sr)
LT (1) LT2805723T (sr)
ME (1) ME01333B (sr)
PT (4) PT3332789T (sr)
RS (1) RS52219B (sr)
SI (1) SI1827461T1 (sr)
UA (1) UA96260C2 (sr)

Also Published As

Publication number Publication date
PT2805723T (pt) 2018-01-25
HUE035859T2 (en) 2018-05-28
CY1125491T1 (el) 2025-05-09
ME01333B (me) 2013-12-20
SI1827461T1 (sl) 2012-05-31
LT2805723T (lt) 2018-02-12
PT1827461E (pt) 2012-05-07
UA96260C2 (ru) 2011-10-25
PT3332789T (pt) 2022-07-05
PT4070800T (pt) 2024-12-30
ES2495392T3 (es) 2014-09-17
ES2666146T3 (es) 2018-05-03
RS52219B (sr) 2012-10-31
ES2382554T3 (es) 2012-06-11
ES2428741T3 (es) 2013-11-11
DK1827461T3 (da) 2012-03-26

Similar Documents

Publication Publication Date Title
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TW200806300A (en) New therapeutic combinations for the treatment of depression
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
ATE547106T1 (de) Cladribin dosierschema zur behandlung von multipler sklerose
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний